NxStage Medical Prepares for Fresenius Merger

NxStage Medical (NASDAQ: NXTM) is in an awkward position right now, and it's one that any investor in a company that has received an acquisition bid can understand. The maker of home dialysis equipment received a buyout offer from industry peer Fresenius Medical Care (NYSE: FMS) earlier this year, but it hasn't stopped the company from pushing ahead with initiatives intended to result in business growth.

NxStage didn't publicize its third-quarter financial report in the same way that it typically does, choosing not to issue a press release and instead just filing the required 10-Q report with the U.S. Securities and Exchange Commission. Shareholders likely weren't happy with the company's performance, but the bigger question is whether there will be any obstacles to getting the Fresenius deal done in the near future. Let's take a closer look at NxStage Medical and how its story is shaping up.

Image source: NxStage Medical.

Source: Fool.com